NOVARTIS

Help us explore a new study treatment for **Huntington's disease.**

As someone living with or caring for someone with Huntington's disease, you know the impact it has on daily life - for both the person with the condition and those closest to them. While current treatments can help manage symptoms, they can't slow the progression of the disease itself. That's why we're conducting INVEST-HD – a Phase 3 clinical study to see if an oral investigational medicine could help slow the progression of Huntington's disease. Research studies like this help us learn more about the condition and may help others in the future.

Who can take part?

We're looking for about

770 people

to join the INVEST-HD study, who, among other criteria:

- Are aged between 21 and 70
- Have a gene-positive test result confirming Huntington's disease, with a CAG repeat length of 40 or above
- Are in the early stages of Huntington's disease (which means having mild or unnoticeable symptoms)



What does taking part involve?

Screening

If an individual chooses to join this study, the study team will first carry out some assessments to see if the study is a good fit for them. If they're not able to take part in this study because they don't meet the study requirements, please don't be discouraged. Other clinical studies may be available, and research in this area continues to advance.

Treatment period

If they're eligible and choose to join, they'll be randomly assigned to receive either the investigational medicine (60% chance) or a placebo (40% chance) to take as tablets every day for up to 3 years. A placebo looks like the investigational medicine but does not contain active medicine. **Regardless of which study medicine the participant is given, they will be able to continue taking their usual Huntington's disease medication(s) throughout the study.**

Participants may choose to have a study companion such as a friend, partner, or relative to accompany and support them throughout the study.

Optional separate study

If the participant completes the treatment period, they may be given the opportunity to join a **separate study** where everyone will receive the investigational medicine, even if they were previously given a placebo.

How will participants' health be monitored?

As with every clinical study, safety is our top priority. You'll have your health carefully monitored at regular clinic visits. Health assessments will vary between visits and may include physical examinations, lumbar punctures, blood samples, and brain magnetic resonance imaging (MRI) scans.

All this expert study-related care, along with regular health monitoring and your assigned study medicine, will be provided at no cost to you for the entire duration of your participation.

What happens next?

We would be grateful if you could share this information with members of your community to raise awareness of the INVEST-HD study.

If you have any questions, or would like to learn more, please contact the study team using the details below. They'll be happy to answer any questions you may have.

Study details can be found by using the QR code or by email at novartis.email@novartis.com

July 2026 - FA-11745927- IRB-MOD04016854

